Steward Partners Investment Advisory LLC Purchases 1,338 Shares of Hologic, Inc. (NASDAQ:HOLX)

Steward Partners Investment Advisory LLC increased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 5.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 25,398 shares of the medical equipment provider’s stock after buying an additional 1,338 shares during the period. Steward Partners Investment Advisory LLC’s holdings in Hologic were worth $1,831,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. General Partner Inc. bought a new position in Hologic during the fourth quarter worth $26,000. Venturi Wealth Management LLC raised its stake in Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 261 shares during the last quarter. First Horizon Advisors Inc. raised its stake in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 134 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 159 shares during the last quarter. Finally, Covestor Ltd raised its stake in Hologic by 23.8% during the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after buying an additional 133 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on HOLX. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Evercore ISI decreased their price target on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research note on Thursday, February 6th. Stephens reaffirmed an “overweight” rating and issued a $84.00 price target on shares of Hologic in a research note on Thursday, February 6th. Morgan Stanley decreased their price target on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Finally, William Blair reaffirmed an “outperform” rating on shares of Hologic in a research note on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Hologic presently has an average rating of “Hold” and a consensus price target of $84.62.

Hologic Stock Up 3.3 %

Hologic stock opened at $64.54 on Friday. Hologic, Inc. has a fifty-two week low of $61.70 and a fifty-two week high of $84.67. The stock has a market cap of $14.48 billion, a PE ratio of 20.36, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The firm’s 50-day simple moving average is $68.19 and its 200 day simple moving average is $75.30. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Research analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.